AbCellera Biologics Inc. ABCL Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -267.6%+1,128pp | -289%+803pp | -739.7%+195pp | -847.6%-32.9pp | -1,395.3%-760pp | |
| Net margin | -181.7%+544pp | -194.9%+370pp | -486%+47.3pp | -503.9%-40.1pp | -726.2%-316pp | |
| EBITDA margin | -237.8%+808pp | -259.5%+553pp | -688.3%-14.1pp | -696.1%-46.7pp | -1,045.5%-477pp | |
| Free cash flow margin | -238.9%+381pp | -231.7%+417pp | -433.4%+165pp | -422.8%+92.8pp | -619.9%-263pp | |
| Returns | ||||||
| Return on equity | -14.7%+0.9pp | -14.5%+0.3pp | -16.8%-1.3pp | -15.6%-2.3pp | -15.6%-3.0pp | |
| Return on assets | -10.9%+1.1pp | -10.8%+0.7pp | -12.5%-0.4pp | -11.8%-1.4pp | -12%-2.0pp | |
| Return on invested capital | -22.5%+10.4pp | -22.3%+8.2pp | -26.2%+3.7pp | -27.3%-1.5pp | -32.9%-11.5pp | |
| Efficiency | ||||||
| Asset turnover | 0.1×0.0× | 0.1×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Liquidity | ||||||
| Current ratio | 14.1×+3.9× | 11.3×+1.5× | 10.1×+0.8× | 11.1×+0.1× | 10.1×+2.4× | |
| Quick ratio | 13.9×+3.7× | 11.2×+1.4× | 10.1×+0.8× | 11.1×+0.1× | 10.1×+2.4× | |
| Cash ratio | 2.2×-0.3× | 2×0.0× | 1.6×-0.3× | 1.8×-0.7× | 2.4×+1.0× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×+0.1× | 0.1×+0.1× | 0.1×+0.1× | 0.1×+0.1× | 0.1×0.0× | |
| Debt-to-assets | 0.1×+0.1× | 0.1×+0.1× | 0.1×+0.1× | 0.1×+0.1× | 0.1×0.0× | |
| Per Share | ||||||
| Book value per share | $3.10-9.9% | $3.24-9.8% | $3.23-11.8% | $3.37-10.7% | $3.44-11.0% | |
| Valuation | ||||||
| Market capitalization | $1.06B+59.2% | $1.02B+18.3% | $1.5B+96.2% | $1.1B+26.2% | $664.51M-49.9% | |
| Enterprise value | $1.1B+100.0% | $1.04B+34.1% | $1.54B+124% | $1.12B+46.0% | $548.09M-56.2% | |
| Price / sales | 13.4×-15.4× | 13.6×-16.4× | 42.6×+19.3× | 33.4×+7.1× | 28.7×-8.3× | |
| Price / book | 1.1×+0.5× | 1.1×+0.2× | 1.6×+0.8× | 1.1×+0.3× | 0.6×-0.5× | |
| EV / sales | 13.8×-9.9× | 13.8×-13.0× | 43.5×+22.7× | 34.2×+10.9× | 23.7×-11.3× | |
| Free cash flow yield | -17.9%+3.7pp | -17%+4.6pp | -10.2%+15.6pp | -12.7%+6.9pp | -21.6%-11.9pp | |
| Earnings yield | -13.6%+11.7pp | -14.3%+4.5pp | -11.4%+11.5pp | -15.1%+2.5pp | -25.3%-14.2pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do AbCellera Biologics Inc.'s ratios come from?
- Every ratio is computed from AbCellera Biologics Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.